Good news for CB 1 receptors: Endogenous agonists are in the right place

Research output: Contribution to journalArticlepeer-review


Endocannabinoids are endogenous ligands of brain-type (CB 1) and spleen-type (CB 2) cannabinoid receptors. N-Arachidonoylethanolamine (anandamide, AEA) and 2-arachidonoylglycerol (2-AG) are prototype members of the fatty acid amides and the monoacylglycerols, two groups of endocannabinoids. Unlike CB 1, CB 2 receptors do not reside within 'caveolae', specialized membrane microdomains that are well-known modulators of the activity of a number of G protein-coupled receptors. In this issue of the British Journal of Pharmacology, Rimmerman and coworkers demonstrate that 2-AG is entirely localized in the caveolae of dorsal root ganglion cells, where also part of AEA (∼30%) can be detected. However, most of AEA (∼70%) was detected in non-caveolae fractions, that is where CB 2 receptors are localized. The different interaction of AEA and 2-AG with membrane microdomains might have significant implications for endocannabinoid-dependent autocrine and/or retrograde-paracrine signalling pathways. It also raises an important question about the structural determinants responsible for a different localization of two apparently similar endocannabinoids within lipid bilayers.

Original languageEnglish
Pages (from-to)179-181
Number of pages3
JournalBritish Journal of Pharmacology
Issue number2
Publication statusPublished - Jan 2008


  • Cannabinoids
  • Caveolae
  • Cholesterol
  • Endocannabinoids
  • Lipid rafts
  • Signal transduction

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'Good news for CB 1 receptors: Endogenous agonists are in the right place'. Together they form a unique fingerprint.

Cite this